Evidence map›Paper›PMID 41403735›Full record

ReviewAdvanced pharmaceutical bulletin2025

Genosomes: An Introspection into Transfection, Future Perspectives and Applications.

Abhirami Subramony, Divyatha Raj, Fiza Fairooz, Aparna Venugopal, Aparna Rajesh, Sreeja C Nair

Abstract readReview
In one paragraph

Review in Advanced pharmaceutical bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abhirami SubramonyAmrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi-682041, India.ORCID https://orcid.org/0009-0005-9049-2081
Divyatha RajAmrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi-682041, India.
Fiza FairoozAmrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi-682041, India.
Aparna VenugopalAmrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi-682041, India.
Aparna RajeshAmrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi-682041, India.
Sreeja C NairAmrita School of Pharmacy, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi-682041, India.ORCID https://orcid.org/0000-0001-9861-0461

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of advanced gene delivery platforms has transformed the precision targeting of therapeutic nucleic acids, such as miRNA, siRNA, and pDNA, for the treatment of genetic and acquired diseases, including cystic fibrosis, malignancies, sickle cell anaemia, and β-thalassemia. Although viral vectors have traditionally dominated this field, non-viral systems, particularly genosomes (cationic lipid-based nanocarriers or lipoplexes), have emerged as promising alternatives due to their enhanced biosafety, lower immunogenic potential, and manufacturability. These nanostructured systems facilitate efficient nucleic acid condensation, protect against enzymatic degradation, and enhance cellular uptake and endosomal escape. Further refinements, including PEGylation, incorporation of helper lipids, and stimuli-responsive formulations, have significantly improved transfection efficiency and tissue-specific delivery. Notable clinical advancements, such as RNA-lipoplexes in cancer immunotherapy and multifunctional envelope-type nanodevices (MEND), highlight their therapeutic potential. This review provides a critical analysis of genosome design strategies, formulation techniques, intracellular trafficking mechanisms, clinical applications, patented innovations, and future prospects to advance genosome-mediated gene therapy.

Indexed as

Cationic liposomeGenosomesLipoplexesTransfection efficiency

Identifiers

PMID41403735
PMCPMC12703403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.